Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial

PURPOSE: A link between poor sleep quality and Alzheimer’s disease (AD) has recently been suggested. Since endogenous melatonin levels are already reduced at preclinical AD stages, it is important to ask whether replenishing the missing hormone would be beneficial in AD and whether any such effects...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Wade, Alan G, Farmer, Mildred, Harari, Gil, Fund, Naama, Laudon, Moshe, Nir, Tali, Frydman-Marom, Anat, Zisapel, Nava
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2014
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4069047/
https://ncbi.nlm.nih.gov/pubmed/24971004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CIA.S65625
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg